Patent application number | Description | Published |
20130129731 | ANTI C-MET ANTIBODY AND USES THEREOF - An anti c-Met antibody or antigen-binding fragment thereof comprising a heavy-chain variable region having heavy-chain complementarity determining region (CDR) amino acid sequences of SEQ ID NOs: 1, 2 and 3, and a light-chain variable region having light-chain CDR amino acid sequences of SEQ ID NOs: 4, 5, and 6; and a method of wound healing, tissue regeneration, or cell proliferation comprising administration of same; as well as related compositions and methods. | 05-23-2013 |
20140105901 | USE OF CBL AS BIOMARKER FOR IDENTIFYING SUBJECT SUITABLE FOR TREATMENT WITH ANTI-C-MET ANTIBODY - A method of identifying a cell sample or a subject suitable for treatment with an anti-c-Met antibody or antigen binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining a Cbl concentration, a Cbl mutation, and/or a mutation of a site of c-Met for interaction with Cbl in a cell sample from a subject, as well as related compositions and methods. | 04-17-2014 |
20140105902 | USE OF LRIG1 AS A BIOMARKER FOR IDENTIFYING A SUBJECT FOR APPLICATION OF ANTI-C-MET ANTIBODIES - A method of identifying a cell sample or subject suitable for treatment with an anti-c-Met antibody or antigen-binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining the presence of LRIG1 in a cell sample from the subject, as well as related methods and compositions. | 04-17-2014 |
20140200156 | GENES INDUCING AGONISTIC EFFECTS BY ANTI-C-MET ANTIBODY TREATMENT AND DRUG SCREENING METHOD USING THE GENES - Biomarkers for screening drugs reducing side effects of anti-c-Met antibodies and a method of screening using the biomarkers, and more particularly, biomarkers commonly enhancing or reducing gene expression and a method of screening anti-c-Met antibodies having reduced side effects using the biomarkers or a method of screening drugs that reduce side effects of anti-c-Met antibodies. | 07-17-2014 |
20140296097 | MARKER FOR DETERMING EFFECTS OF ANTI-C-MET ANTIBODY AND METHOD OF DETERMING EFFECTS OF ANTI-C-MET ANTIBODY USING THE MARKER - There are provided a composition for determining the efficacy of a c-Met antibody including marker genes and a method for determining the efficacy of a c-Met antibody using the marker genes. | 10-02-2014 |
20140302030 | METHOD OF COMBINATION THERAPY USING ANTI-C-MET ANTIBODY AND SORAFENIB - Provided is a method of combination therapy for prevention or treatment of a cancer including or consisting essentially of co-administering sorafenib and an anti-c-Met antibody or an antigen-binding fragment thereof to a subject. The method of combination therapy can achieve an excellent synergistic effect and lower the effective dose of the anti-c-Met antibody, thereby enabling a more effective cancer treatment. | 10-09-2014 |
20140308284 | METHOD OF COMBINATION THERAPY USING ANTI-C-MET ANTIBODY AND FGFR INHIBITOR - Provided is a method for prevention or treatment of a cancer, comprising co-administering (a) an FGFR inhibitor and (b) an anti-c-Met antibody or antigen-binding fragment thereof to a subject in need thereof, wherein the anti-c-Met antibody or the antigen-binding fragment thereof specifically binds to an epitope comprising 5 or more contiguous amino acids within the SEMA domain of c-Met protein. | 10-16-2014 |
20150212077 | BIOMARKER TFF1 FOR PREDICTING EFFECT OF C-MET INHIBITOR - A method of predicting an effect of a c-Met inhibitor and/or selecting a subject for application of a c-Met inhibitor using TFF1, a method of monitoring an effect of a c-Met inhibitor using TFF1, and a method of treating and/or preventing cancer including administering a c-Met inhibitor to the selected subject. | 07-30-2015 |